Short Interest in ImmuCell Corporation (NASDAQ:ICCC) Rises By 147.1%

ImmuCell Corporation (NASDAQ:ICCC) was the recipient of a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 15,418 shares, a growth of 147.1% from the November 30th total of 6,239 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily volume of 18,731 shares, the days-to-cover ratio is currently 0.8 days. Based on an average daily volume of 18,731 shares, the days-to-cover ratio is currently 0.8 days. Approximately 0.2% of the shares of the company are short sold.

Hedge Funds Weigh In On ImmuCell

An institutional investor recently raised its position in ImmuCell stock. Geode Capital Management LLC boosted its holdings in ImmuCell Corporation (NASDAQ:ICCC) by 4.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 71,852 shares of the biotechnology company’s stock after buying an additional 2,907 shares during the period. Geode Capital Management LLC owned approximately 0.79% of ImmuCell worth $500,000 as of its most recent SEC filing. 13.47% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of ImmuCell in a research note on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, ImmuCell presently has an average rating of “Sell”.

ImmuCell Price Performance

ICCC stock traded up $0.32 during trading on Friday, hitting $6.12. The stock had a trading volume of 336,206 shares, compared to its average volume of 14,761. ImmuCell has a 1-year low of $4.28 and a 1-year high of $7.60. The stock has a market cap of $55.39 million, a price-to-earnings ratio of 23.54 and a beta of 0.20. The company’s 50 day moving average price is $5.69 and its two-hundred day moving average price is $6.14. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.76 and a current ratio of 4.21.

ImmuCell (NASDAQ:ICCC) last released its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. The business had revenue of $5.51 million during the quarter. ImmuCell had a return on equity of 8.00% and a net margin of 8.37%.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.